AI assistant
CSL Ltd. — Capital/Financing Update 2022
May 11, 2022
17854_rns_2022-05-11_8b30664e-c96a-4422-aaee-63e18b96fa54.pdf
Capital/Financing Update
Open in viewerOpens in your device viewer
For immediate release
11 May 2022
==> picture [205 x 32] intentionally omitted <==
==> picture [58 x 30] intentionally omitted <==
==> picture [262 x 27] intentionally omitted <==
Update Regarding Vifor Pharma Acquisition
CSL Limited (ASX: CSL; USOTC:CSLLY) has previously advised that it expected to be in a position to close the acquisition of Vifor Pharma AG by June 2022. CSL now expects the regulatory approval process to take a few more months.
CSL remains confident of completing its acquisition of Vifor Pharma AG and looks forward to expanding its presence in the rapidly growing nephrology market, as well as leveraging the companies’ combined expertise to continue to deliver innovative solutions to rare and serious illness.
ENDS
Authorised by Fiona Mead Company Secretary
FURTHER INFORMATION
For further information, please contact:
Investors: Media: Bernard Ronchi Jimmy Baker Associate Director, Investor Relations Communications, Asia Pacific CSL Limited CSL Limited Telephone: +613 9389 3470 Mobile +61 450 909 211 Email: [email protected] Email: [email protected]
==> picture [99 x 7] intentionally omitted <==
280171488v.2